Factors for Consideration When Selecting Patients with mCRPC for Treatment With Cabazitaxel

Neal Shore, MD, FACS, explains the treatment regimen he would have chosen for the patient with mCRPC in the presented case, and what factors he uses to inform treatment decision-making.

EP: 1.Case Presentation: A 74-Year-Old Man With Metastatic Prostate Cancer

EP: 2.Available Treatment Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy

EP: 3.Cabazitaxel for the Treatment of mCRPC: Data From the PROSELICA and FIRSTANA Trials

EP: 4.Cabazitaxel for the Treatment of mCRPC: Data From the CARD Trial

Now Viewing

EP: 5.Factors for Consideration When Selecting Patients with mCRPC for Treatment With Cabazitaxel

EP: 6.Selecting Between Treatment With Cabazitaxel or Radiotherapy for Patients with mCRPC

EP: 7.The Evolution of AR Pathway Inhibitors and Docetaxel Utilization in mCRPC Treatment and the Impact on Cabazitaxel

EP: 8.Unmet Needs and Clinical Pearls in mCRPC

Related Videos

Related Content

Advertisement

May 20th 2025

Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer

Hannah Clarke

Results from the phase 3 AMPLIFY trial are intended to support an application to the FDA for potential approval of 64Cu-SAR-bisPSMA.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

May 19th 2025

Study shows value of precision-based approaches in prostate cancer

Hannah Clarke

The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

May 15th 2025

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Tracey L. Krupski, MD Jeunice Owens-Walton, MD

"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.

May 13th 2025

MRI and focal therapy may enable men on AS to safely delay surgery or radiation

Hannah Clarke

Use of focal therapy was shown to prolong the duration of active surveillance.

Related Content

Advertisement

May 20th 2025

Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer

Hannah Clarke

Results from the phase 3 AMPLIFY trial are intended to support an application to the FDA for potential approval of 64Cu-SAR-bisPSMA.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

May 19th 2025

Study shows value of precision-based approaches in prostate cancer

Hannah Clarke

The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

May 15th 2025

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Tracey L. Krupski, MD Jeunice Owens-Walton, MD

"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.

May 13th 2025

MRI and focal therapy may enable men on AS to safely delay surgery or radiation

Hannah Clarke

Use of focal therapy was shown to prolong the duration of active surveillance.